Sun Pharma Corporate Overview
Financial Ratios
SUN
PHARMA
FY17
FY18
FY19**
FY20
FY21
Growth (%)
Sales
8.5
(13.9)
10.1
12.7
2.5
Gross Profit
2.7
(15.8)
11.7
10.9
5.9
EBITDA
16.1
(40.9)
14.3
9.3
25.5
Net Profit
53.2
(69.9)
27.2
41.3
(22.9)
Net Profit (Adjusted)
33.1
(52.6)"
17.5#
3.8#
47.4#
Margins (%)
Gross Margin
73.1
71.5
72.6
71.4
73.8
EBITDA Margin (%)
29.0
19.9
20.7
20.0
24.5
Net Margin
23.0
8.0
9.3
11.6
8.8
Net Margin (Adjusted)
23.0
12.7#
13.5"
12.5#
17.9'
Return (%)
ROCE
21.8
11.1
11.8
11.0
13.5
ROE
19.8
8.7
9.4
9.1
12.5
Others
Debt/Equity
0.22
0.25
0.24
0.17
0.07
Fully Diluted EPS
28.9
8.7
11.1
15.7
12.1
Fully Diluted EPS (Adjusted)
28.9
13.8#
16.2#
16.8#
24.7"
R&D Spend % of Net Sales
7.6
8.6
6.9
6.1
6.5
Revenue
7.1
7.9
6.6
6.0
6.4
Capital
0.6
0.7
0.3
0.1
0.1
# FY18 - Adjusted for Rs. 12.1 bn provision related to Modafinil settlement & deferred tax adjustment
# FY19 - Adjusted for Rs. 12 bn provision related to Modafinil settlement
**FY19 - Includes a one-time sales reduction of Rs. 10,850mn related to change in distribution for India business
#FY20 - Adjusted for Rs. 2.6 bn provision (related to Dusa US DoJ settlement of Rs. 1.6 bn and Indirect Tax provision of Rs. 1.0 bn in India)
#FY21 - Adjusted for Rs. 30.3 bn provision (related to Taro US - DOJ & MDL settlement Rs. 42.2, Rs. 0.9 bn provision related to UK Citalopram case, Rs. 4.1 bn related to
deferred tax gain. Taro provisions are adjusted for minority interest)
© Sun Pharmaceutical Industries Limited. All Rights Reserved.
47View entire presentation